|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-24.84/-10.40
|
企業價值
215.08M
|
資產負債 |
每股賬面淨值
-3.22
|
現金流量 |
現金流量率
--
|
損益表 |
收益
83.81M
|
每股收益
2.22
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|

同行比較之報價最少15分鐘延遲
業務概覽
|
|||
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing, and commercializing potentially transformative gene therapies for severe genetic diseases. |